TW200914378A - Use of hydrophobins as auxil auxiliaries in the crystallization of solids - Google Patents
Use of hydrophobins as auxil auxiliaries in the crystallization of solids Download PDFInfo
- Publication number
- TW200914378A TW200914378A TW097118950A TW97118950A TW200914378A TW 200914378 A TW200914378 A TW 200914378A TW 097118950 A TW097118950 A TW 097118950A TW 97118950 A TW97118950 A TW 97118950A TW 200914378 A TW200914378 A TW 200914378A
- Authority
- TW
- Taiwan
- Prior art keywords
- hydrophobin
- solid
- aqueous phase
- fusion
- gypsum
- Prior art date
Links
- 239000007787 solid Substances 0.000 title claims abstract description 39
- 238000002425 crystallisation Methods 0.000 title claims abstract description 19
- 230000008025 crystallization Effects 0.000 title claims abstract description 18
- 239000008346 aqueous phase Substances 0.000 claims abstract description 24
- 229910052602 gypsum Inorganic materials 0.000 claims abstract description 23
- 239000010440 gypsum Substances 0.000 claims abstract description 23
- 101710091977 Hydrophobin Proteins 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 35
- 230000004927 fusion Effects 0.000 claims description 34
- 239000002671 adjuvant Substances 0.000 claims description 8
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims description 7
- 239000003546 flue gas Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000006477 desulfuration reaction Methods 0.000 claims description 6
- 230000023556 desulfurization Effects 0.000 claims description 6
- 239000007791 liquid phase Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 3
- 239000012752 auxiliary agent Substances 0.000 claims description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 239000013078 crystal Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 235000018417 cysteine Nutrition 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 101710195795 Hydrophobin-B Proteins 0.000 description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 101710195603 Hydrophobin A Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000003000 inclusion body Anatomy 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101100059802 Chlamydophila caviae (strain ATCC VR-813 / DSM 19441 / GPIC) groEL1 gene Proteins 0.000 description 1
- 101100365080 Clostridium perfringens (strain 13 / Type A) scpB gene Proteins 0.000 description 1
- 101100387133 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) dewA gene Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229910052925 anhydrite Inorganic materials 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- AZHSSKPUVBVXLK-UHFFFAOYSA-N ethane-1,1-diol Chemical compound CC(O)O AZHSSKPUVBVXLK-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 101150077981 groEL gene Proteins 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 101150019385 hypB gene Proteins 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006259 organic additive Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000009751 slip forming Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F11/00—Compounds of calcium, strontium, or barium
- C01F11/46—Sulfates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D53/00—Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols
- B01D53/34—Chemical or biological purification of waste gases
- B01D53/46—Removing components of defined structure
- B01D53/48—Sulfur compounds
- B01D53/50—Sulfur oxides
- B01D53/507—Sulfur oxides by treating the gases with other liquids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F11/00—Compounds of calcium, strontium, or barium
- C01F11/18—Carbonates
- C01F11/182—Preparation of calcium carbonate by carbonation of aqueous solutions and characterised by an additive other than CaCO3-seeds
- C01F11/183—Preparation of calcium carbonate by carbonation of aqueous solutions and characterised by an additive other than CaCO3-seeds the additive being an organic compound
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F11/00—Compounds of calcium, strontium, or barium
- C01F11/46—Sulfates
- C01F11/466—Conversion of one form of calcium sulfate to another
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/01—Particle morphology depicted by an image
- C01P2004/02—Particle morphology depicted by an image obtained by optical microscopy
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/30—Particle morphology extending in three dimensions
- C01P2004/40—Particle morphology extending in three dimensions prism-like
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/54—Particles characterised by their aspect ratio, i.e. the ratio of sizes in the longest to the shortest dimension
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Geology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biomedical Technology (AREA)
- Environmental & Geological Engineering (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Health & Medical Sciences (AREA)
- Peptides Or Proteins (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
200914378 九、發明說明: 【發明所屬之技術領域】 本發明係關於疏水蛋白在固體結晶過程中作爲補助劑 用途,特定言之’從水相中製造石膏之用途。 【先前技術】 精細固體的性質主要由組成固體的晶體大小與特性決 定。大小與特性主要影響固體懸浮液的流變性質,從水性 懸浮液中移除(例如過濾)固體之難易度,乾產物的處理及 固體本身的性質。例如色料的顏色強度或分散性主要由單 個晶體的大小與特性決定。 原則上,已知使用適宜的無機或有機添加劑會影響從溶 液中沉澱或結晶過程中形成的晶體大小及特性。此處可參 考例如紐約 2006, Weinheim,Wiley-VCH,Electronic發行, 2006 第 7 版,Ullmann,s Encycl〇pedia 〇f ㈣她…200914378 IX. INSTRUCTIONS OF THE INVENTION: TECHNICAL FIELD OF THE INVENTION The present invention relates to the use of hydrophobin as a supplement in the solid crystallization process, specifically for the purpose of producing gypsum from an aqueous phase. [Prior Art] The properties of fine solids are mainly determined by the crystal size and characteristics of the constituent solids. The size and characteristics primarily affect the rheological properties of the solid suspension, the ease with which the solid suspension is removed (e. g., filtered), the dry product treatment, and the nature of the solid itself. For example, the color strength or dispersibility of a colorant is mainly determined by the size and characteristics of a single crystal. In principle, it is known that the use of suitable inorganic or organic additives affects the size and characteristics of the crystals formed during precipitation or crystallization from the solution. See, for example, New York 2006, Weinheim, Wiley-VCH, Electronic, 2006, 7th edition, Ullmann, s Encycl〇pedia 〇f (d) her...
Chemistry 中"Crystallization and Precipitati〇n_4 4 CrystalChemistry"Crystallization and Precipitati〇n_4 4 Crystal
Habit Modification"。 對石膏晶體的大小與特性的影響為一個經深入研究的方 法(參見實例 G.A· Bertoldi,Zement-Kalk-Gips,Nr. 12, 1978)。目刖在煙氣脫硫中會產生大量石膏的水性懸浮 液為進一步使用,石膏需從水相中分離。該石膏通常為 針形結晶。1^4,183,908及〇8 5,246,677揭示使石膏以緻密 晶體形式結晶之方法,經由加入聚磷酸鹽、有機磷酸鹽或 膦酸鹽,促進從水相中移除石膏。 131092.doc 200914378 疏水蛋白為出現在絲狀真菌(例如裂稽菌(練鄉㈣謂 乃中的約⑽至m個胺基酸的小蛋白質。此等通 常八有8個半胱胺酸單%。疏水蛋白可從天,然來源中分 離 < 是此等亦可藉由例如WO 2006/082251或WO 2006/131564揭示的基因工程方法得到。 先刖技術建議疏水蛋白於多種應用之用途。 WO 96/41882建議疏水蛋白作爲乳化劑、增稠劑或界面 活性劑之用途,為疏水表面賦與親水性質、改善親水基質 的抗^生、製備水包油乳液或油包水乳液。進一步建議包 含醫藥上的應用,如:軟膏或乳霜之製備及化妝品上的應 用’例如皮膚保養品或洗髮精或潤絲精的製造。 Μ 1 252 516揭示在30至8旳的溫度下使用含疏水蛋白 的溶液塗覆多種基質。 '步建°義匕3例如作爲去乳化劑(WO 2006/103251)、 蒸發阻滯劑(W〇 2006/128877)或沾污抑制劑(w〇2嶋⑽ L) 之用途。 7 疏水蛋白作爲結晶輔助劑之用途至今未揭示。 【發明内容】 μ ° 本發明之目的係提供影響結晶的新穎輔助劑。 【實施方式】 。人已發現》亥目的可藉由疏水蛋白在固體結晶過程 爲輔助劑之用途達到。 乍 本發明之進-步實施例為一種從水相 從水相中分離所形成固體之方法,其中該水相中已添二 131092.doc 200914378 該水相總量0.001重晉。/ ε , 土 置/〇至1重1 %之至少一種可溶於該水 相之輔助劑,該等輔λ 寻稀助劑中至少一種包含疏水蛋白。 在本發明—項較佳實施例中,該方法為-種製造石膏之 «玄方法特別佳為煙氣脫硫方法中之一步驟。 本發明細節描述如下: 文中所用的術語,,疏水蛋白"指具有以下的結構通式⑴的 多肽Habit Modification". The effect on the size and properties of gypsum crystals is an in-depth study (see example G.A. Bertoldi, Zement-Kalk-Gips, Nr. 12, 1978). It is seen that in the flue gas desulfurization, an aqueous suspension of a large amount of gypsum is produced for further use, and the gypsum needs to be separated from the aqueous phase. The gypsum is usually needle crystal. 1^4, 183, 908 and 〇 8 5, 246, 677 disclose a method of crystallizing gypsum in the form of dense crystals by promoting the removal of gypsum from the aqueous phase via the addition of polyphosphates, organophosphates or phosphonates. 131092.doc 200914378 Hydrophobin is a small protein that occurs in filamentous fungi (such as about 10 to m amino acids in the genus (4). These usually have 8 cysteines alone. The hydrophobin can be isolated from the source of the <is such that it can also be obtained by genetic engineering methods such as disclosed in WO 2006/082251 or WO 2006/131564. The prior art suggests the use of hydrophobins in a variety of applications. 96/41882 recommends the use of hydrophobins as emulsifiers, thickeners or surfactants, imparting hydrophilic properties to hydrophobic surfaces, improving the resistance of hydrophilic matrices, preparing oil-in-water emulsions or water-in-oil emulsions. Further recommendations include Pharmaceutical applications such as the preparation of ointments or creams and cosmetic applications such as the manufacture of skin care products or shampoos or conditioners. Μ 1 252 516 discloses the use of hydrophobics at temperatures of 30 to 8 Torr. The solution of the protein is coated with a variety of matrices. 'Step construction 匕 3 for example as a demulsifying agent (WO 2006/103251), evaporative retarder (W〇2006/128877) or stain inhibitor (w〇2嶋(10) L ) use of 7 hydrophobins The use of a crystallization adjuvant has not been disclosed so far. [Invention] The object of the present invention is to provide a novel adjuvant which affects crystallization. [Embodiment] It has been found that the purpose of the hydrolytic protein in the solid crystallization process is The use of the adjuvant is achieved. 进 The further embodiment of the invention is a method for separating the solid formed from the aqueous phase from the aqueous phase, wherein the aqueous phase has been added two 131092.doc 200914378. The total amount of the aqueous phase is 0.001. 。, ε, soil/〇 to at least 1% of at least one auxiliary agent soluble in the aqueous phase, at least one of the auxiliary λ-seeking assistants comprising hydrophobin. In the present invention - preferred embodiment In the method, the method of making a gypsum is particularly preferred as one of the steps of the flue gas desulfurization method. The details of the invention are as follows: The term as used herein, hydrophobin " has the following structural formula (1) Peptide
VCi-X1.50.C^X〇-5^.X1.1〇〇.C4.Xi i〇〇 c^Xi ^ce x〇 s C7_x ^ (丨) 其中X為20種天然胺基酸(Phe、Leu、Ser、Tyr、CyS、VCi-X1.50.C^X〇-5^.X1.1〇〇.C4.Xi i〇〇c^Xi ^ce x〇s C7_x ^ (丨) where X is 20 natural amino acids (Phe , Leu, Ser, Tyr, CyS,
Trp、pr。、Hls、Gin、Arg、以、胸、w、細、_、Trp, pr. , Hls, Gin, Arg, I, Chest, w, Fine, _,
Va卜Ala、Asp、Glu、Gly)中任一種。每個x可相同或不 同一在每種情況下,緊鄰χ的指數為胺基酸的數目,匸代 半胱fe S欠丙胺酸、絲胺酸、甘胺酸、曱硫胺酸或蘇胺 k仁其限制條件為C所代表的殘基中至少四個為半脱胺 S文,且指數11與〇1分別為〇至500之間的自然數,較佳為15至 3 00之間。 通式⑴多肽進一步特徵為(塗覆玻璃表面後)水滴接觸角 比同等大小水滴與未塗覆玻璃表面所形成接觸角至少增加 2〇 ,較佳為至少25。及更佳為至少30。’其中每次測定均 在至溫下進行。 代表C至C8的胺基酸較佳為半胱胺酸;但此等亦可經類 似體積的其他胺基酸代替,較佳為丙胺酸、絲胺酸、蘇胺 酉文、甲硫胺酸或甘胺酸。但是,C1至C8位置中至少四個, 131092.doc 200914378 較佳為至少5個,更佳為至少6個及最佳為至少?個由半耽 胺酸組成。根據本發明制的蛋白質巾半胱胺酸可呈還原 形式存在或彼此形成二硫鍵。分子内形成c_c鍵最佳,尤 其此包含至少一個’較佳為2個,更佳為3個及最佳為4個 刀子内一石瓜鍵。右上述以類似體積的胺基酸替㉟半耽㈣ 時,在成對交換中涉及的位置處有利於彼此間形成分子 内的二硫鍵。Any of Va Bu Ala, Asp, Glu, Gly). Each x may be the same or different. In each case, the index of the χ next to the χ is the number of amino acids, and the deuterated feta fe S is owed to alanine, serine, glycine, guanine or sulphamine. The k-restriction condition is that at least four of the residues represented by C are semi-deaminized S text, and the indices 11 and 〇1 are respectively a natural number between 〇 and 500, preferably between 15 and 300. The polypeptide of the formula (1) is further characterized in that the contact angle of the water droplets (after coating the surface of the glass) is at least 2 Å, preferably at least 25, greater than the contact angle formed by the water droplets of the same size and the surface of the uncoated glass. And better at least 30. Each of these measurements was carried out at ambient temperature. The amino acid representing C to C8 is preferably cysteine; however, these may be replaced by similar amounts of other amino acids, preferably alanine, serine, sulphate, methionine. Or glycine. However, at least four of the C1 to C8 positions, 131092.doc 200914378 are preferably at least 5, more preferably at least 6, and most preferably at least? One consists of a semi-phosphoric acid. The protein towel cysteine produced according to the present invention may exist in a reduced form or form a disulfide bond with each other. The formation of the c_c bond in the molecule is optimal, and in particular comprises at least one 'preferably two, more preferably three and most preferably four guaia bonds in the knife. When the above-mentioned similar volume of amino acid is used for 35 耽 (4), it is advantageous to form intramolecular disulfide bonds at positions involved in the pair exchange.
备X表不的位置為半胱胺酸、絲胺酸、丙胺酸、甘胺 酸、甲硫胺酸或蘇胺酸時,通式中每個C —位置處數值可作 相應改變。 本發明一項較佳具體實施例可使用通式(11)疏水蛋白 X«-C1.X3-25-C2-X〇,2-C3-X5.6〇-C-»-X2.3S.C5.X2.15-Ce.X0.2-C?-X3.35.C8*Xm (Ιί) 其中X、c及緊鄰X及C的指數如上定義,指數ηΛιη代表〇 至350之間的數值,較佳為15至3〇〇之間,且該等蛋白質進 一步經上述接觸角變化區別,c表示的殘基中至少六個包 含半胱胺酸。所有C殘基均含有半胱胺酸特別佳。 特別佳為使用通式(III)疏水蛋白When the position of the X-form is cysteine, serine, alanine, glycine, methionine or threonine, the value at each C-position in the formula can be changed accordingly. A preferred embodiment of the present invention can use the hydrophobin of the general formula (11) X«-C1.X3-25-C2-X〇, 2-C3-X5.6〇-C-»-X2.3S.C5 .X2.15-Ce.X0.2-C?-X3.35.C8*Xm (Ιί) where X, c and the index immediately adjacent to X and C are as defined above, and the index ηΛιη represents the value between 〇 and 350. Preferably, it is between 15 and 3 Torr, and the proteins are further distinguished by the above contact angle change, and at least six of the residues represented by c comprise cysteine. It is particularly preferred that all C residues contain cysteine. It is especially preferred to use the hydrophobin of formula (III)
Xn-C1-X^9-C2-C3-Xii.3rC4-X2-2rC5-X5-rC6-C7-X&.i8-C8-Xm <") 其中X、C及緊鄰X的指數如上定義,指數n&m代表〇至2〇〇 之間的數值,該等蛋白質進一步經上述接觸角變化區別且 C表示的殘基中至少六個為半胱胺酸。c表示的所有殘基 均為半胱胺酸時特別佳。 131092.doc 200914378 J基Xn及Xm為可與疏水蛋白自然連接的肽序列。但是, 中—個或兩者可為未與疏水蛋白自 序列。亦包合χ β ^ Jn η或Xm殘基,其中該肽序列自然發生在 =白中,該(等)殘基經未自然發生在疏水蛋 肽 斤列延長。 算或Μ未與疏水蛋白自然連接的肽序列時,該 A酸般為至少2G個胺基酸,較佳為至少35個胺 基。例如,此算·^生 了為20至500個,較佳為30至400個且最 佳為35至1〇〇個胺基酸 ^ ^ ^ # -λ-, 斤歹未與疏水蛋白自然連接的 亦指以下的融合對象。此顯示該蛋白質由至少一 個疏水蛋白部分與非鈇έ士人 ^ ,、,、、,。〇之融合對象部分組成。由融 口 W冢及疏水蛋白部合έ日士、& _丄人 刀、,且成的嘁合疏水蛋白揭示在例如 ;〇 wo 2〇〇6/082253 ,WO 2006/131564 中〇 二:對“分可選自多種蛋白質。可能僅有一個融合對 '、疏水蛋白部分連接或有複數個融合對象可與疏水蛋 白部分連接,例如盥踣匕 ” 1火蛋白邛分的胺基末端(xn)及羧基 木嗬(入連接。但,亦 一方了此例如,將兩個融合對象與根據 本發明蛋白質中一個位置(mm)連接。 特別適合的融合對象為自'然存在於微生物中的蛋白質, 尤2大腸桿菌或枯草桿菌。該等融合對象實例為 Γ( 6/082251 中 seqidn〇:i6)、㈣彻觸細 51 、+…丨以 乳化還原蛋白。極度適合的亦為上 …、片斷或其衍生物’其僅包含該等序列一部分,例 I31092.doc 200914378 如70%至99%、較佳為5%至5〇%及更佳為1〇%至4〇%,或其 中的個別胺基酸或核苷酸相對於上述序列已經修改,該等 百分比分別以胺基酸數量計算。 在另-較佳實施例中,融合疏水蛋白不僅具有上述融合 對象’亦具有以親和標簽/尾端形式的親和性功能部位, 如xn或xm中一個基團或如該基團的末端成分。親和標簽或 尾端(原則上已知)包含可與一些互補基團相互作用的錨定 基團且利於處理及純化蛋白質。該等親和性功能部位之實 例包 3 (His)k、(Arg)k、(Asp)k、(Phe)d (Cys)k基團,其中 k-般為UH)之間的自然數。⑴叫基團中k在4至6之間較 佳。xn及/或x„基團可僅由該親和性功能部位組成,或由 與疏水蛋白自然或未自然連接的x^Xm殘基經位於末端的 親和性功能部位延長。 根據本發明作爲疏水蛋白或其衍生物使用的蛋白質可進 一步修飾該等多肽序列,例如經糖化反應、乙醯化作用或 進行化學交聯,例如與戊二搭交聯。 根據本發明使用的疏水蛋白或其料物之特性為當表面 塗覆該等蛋白質時,表面特性會改變。表面屬性的改變可 經實驗確定,例如在表面塗覆蛋白質之前及之㈣量水滴 接觸角及確定兩次測量間的差異。 S此相關技藝之人士原則上咸了解如何測量接觸角。該 、J里與至/里、水滴及作爲基質使用的玻璃板相關。適合例 如.測$接觸角的方法的精確實驗條件說明於實驗部分。 在文中所述的條件下,根據本發明使用的融合蛋白之特性 131092.doc 200914378 為在每個情況下,接觸角比同等大小的水滴與未塗覆玻璃 表面的接觸角增加至少20。’較佳為至少25。且最佳為至少 30〇 〇 本發明具體實施例中的最佳疏水蛋白為dewA、r〇dA、 hyPA ' hypB、SC3、basfl、basf2類型疏水蛋白。包含此等 序列的疏水蛋白揭示於例如:WO 2006/82251中。除非另 説明’否則下文所提及之序列與w〇 2〇〇6/82251中所揭示 之序列相關。描述SEq_id編號的總表見w〇 2〇〇6/82251中 (' 第20頁。 特別適合根據本發明的為具有括號内的多肽序列及為其 編碼的核苷酸序列(尤其根據SEQ ID N〇:19、21、23的序 列)的融合蛋白 yaad_Xa_dewA_his(SEQ ID n〇 2())、Xn-C1-X^9-C2-C3-Xii.3rC4-X2-2rC5-X5-rC6-C7-X&.i8-C8-Xm <") where X, C and the index immediately adjacent to X are as defined above The index n&m represents a value between 〇 and 2 ,, the proteins are further distinguished by the above contact angle change and at least six of the residues represented by C are cysteine. It is particularly preferred that all residues represented by c are cysteine. 131092.doc 200914378 J-based Xn and Xm are peptide sequences that are naturally linked to hydrophobins. However, the medium or both may be self-sequenced with the hydrophobin. Also included is a ^β^Jn η or Xm residue, wherein the peptide sequence naturally occurs in = white, and the (etc.) residue is extended naturally by the hydrophobic egg peptide. In the case of a peptide sequence which is not naturally linked to a hydrophobin, the A acid is at least 2G amino acids, preferably at least 35 amine groups. For example, this calculation is 20 to 500, preferably 30 to 400, and most preferably 35 to 1 amino acid ^ ^ ^ # -λ-, which is not naturally linked to hydrophobin. Also refers to the following fusion objects. This shows that the protein consists of at least one hydrophobin moiety with a non-gentleman ^ , , , , , . The composition of the fusion object is composed. The fusion hydrophobin formed by the fusion of W and the hydrophobin portion of the Japanese gems, & _ human knives, is disclosed in, for example, 〇wo 2〇〇6/082253, WO 2006/131564 〇 2: The "minus can be selected from a variety of proteins. There may be only one fusion pair", the hydrophobin moiety is linked or there are a plurality of fusion objects that can be linked to the hydrophobin moiety, such as the amino terminus of the 火"1 fire protein quinone (xn And carboxyl lignin (into the junction. However, one side of this, for example, two fusions are linked to a position (mm) in the protein according to the invention. A particularly suitable fusion object is a protein that is present in the microorganism. , especially 2 Escherichia coli or Bacillus subtilis. Examples of such fusion objects are Γ (6/082251 in seqidn〇: i6), (4) 细细细51, +...丨 to emulsify reduced protein. Extremely suitable is also... Or a derivative thereof, which comprises only a portion of the sequence, such as I31092.doc 200914378, such as 70% to 99%, preferably 5% to 5%, and more preferably 1% to 4%, or an individual thereof Amino acids or nucleotides have been modified relative to the above sequences, such The fractions are each calculated as the amount of amino acid. In another preferred embodiment, the fusion hydrophobin has not only the fusion object described above but also an affinity functional site in the form of an affinity tag/tail, such as a base in xn or xm a group or a terminal component such as the group. The affinity tag or tail (previously known) comprises an anchor group which interacts with some of the complementary groups and facilitates processing and purification of the protein. Examples of such affinity functional sites A natural number between the 3 (His)k, (Arg)k, (Asp)k, (Phe)d (Cys)k groups, where k- is UH). (1) It is preferable that k is between 4 and 6 in the group. The xn and/or x„ group may consist solely of the affinity functional site or the X^Xm residue naturally or unnaturally linked to the hydrophobin is extended by the terminally located affinity functional site. According to the invention as a hydrophobin The protein used in the derivative or derivative thereof may further modify the polypeptide sequence, for example, by saccharification reaction, acetylation or chemical crosslinking, for example, crosslinking with glutarylene. Hydrophobin or a material thereof used according to the present invention The characteristic is that the surface properties change when the surface is coated with the proteins. The change in surface properties can be determined experimentally, for example, before the surface is coated with the protein and (4) the contact angle of the water droplets and the difference between the two measurements is determined. The person skilled in the art knows in principle how to measure the contact angle. This, J is related to the to/in, the water droplets and the glass plate used as the substrate. The precise experimental conditions suitable for, for example, the method of measuring the contact angle are illustrated in the experimental part. Under the conditions described herein, the properties of the fusion protein used according to the invention 131092.doc 200914378 are in each case the contact angle is equal to the size The contact angle of the water droplets to the uncoated glass surface is increased by at least 20. 'preferably at least 25. And optimally at least 30. The optimal hydrophobin in the embodiment of the invention is dewA, r〇dA, hyPA 'hypB Hydrophobins of the SC3, basfl, basf2 type. Hydrophobins comprising such sequences are disclosed, for example, in WO 2006/82251. Unless otherwise stated, the sequences mentioned below are disclosed in w〇2〇〇6/82251 Sequence correlation. A summary of the SEq_id number is given in w〇2〇〇6/82251 ('page 20. Particularly suitable for the polypeptide sequence in parentheses and the nucleotide sequence encoded thereby in accordance with the invention (especially a fusion protein yaad_Xa_dewA_his (SEQ ID n〇2()) according to the sequence of SEQ ID N〇: 19, 21, 23,
Xa-n>dA-his(SEQ ID NO:22)或 yaad_Xa_basfKhis(SEQ ID NO.24)。特別佳為使用 yaa(j_xa_dewA_his(SEQ ID NO.20)。 同樣,特別佳具體實施例為由SEQ ID N〇:2〇、22或24中所 〇 示的多肽序列中經交換、插入或去除至少一個,高達1〇 個,較佳為5個,更佳為總胺基酸的5%且仍具有起始蛋白 質至少50%的生物性質之所得蛋白質為最佳實例。文中蛋 白質的生物性質咸了解係指接觸角至少改變2〇。。 特別適宜本發明具體實施例的衍生物為由%以_乂心 dewA-his(SEQ ID NO:20) . yaad-Xa-rodA-his(SEQ ID NO:22)或 yaad-Xa_basfl_his(SEQ ID N〇:24)融合 對象所衍生的衍生物。可能有利之作法為改用經截斷的 yaad殘基代替具有294個胺基酸的完整”“融合對象 131092.doc -12- 200914378 ID NO: 1 6)。但是,經截斷的殘基應具有至少2〇個,較佳 為至少3 5個胺基酸。例如,可使用具有2〇至293個,較佳 為25至250個,更佳為35至150個胺基酸(例如35至1〇〇個胺 基酸)經截斷的殘基。該蛋白質實例之一為具有截斷至4〇 個胺基自义的 yaad 殘基的 yaad40-Xa-dewA-his(PCT/EP 2006/064720 中 SEQ ID ΝΟ··26)。 可利用疏水蛋白與一個或多個融合對象之間的分裂點分 離融合對象及釋放未衍化型的純疏水蛋白(例如BrCN分裂Xa-n>dA-his (SEQ ID NO: 22) or yaad_Xa_basfKhis (SEQ ID NO. 24). It is particularly preferred to use yaa (j_xa_dewA_his (SEQ ID NO. 20). Likewise, a particularly preferred embodiment is the exchange, insertion or removal of at least the polypeptide sequence set forth in SEQ ID N: 2〇, 22 or 24 A protein of up to 1 ,, preferably 5, more preferably 5% of the total amino acid and still having a biological property of at least 50% of the starting protein is the best example. Means that the contact angle changes by at least 2 〇. Particularly suitable derivatives of the specific examples of the invention are % 以 heart dewA-his (SEQ ID NO: 20). yaad-Xa-rodA-his (SEQ ID NO: 22) or yaad-Xa_basfl_his (SEQ ID N〇: 24) a derivative derived from a fusion object. It may be advantageous to use a truncated yaad residue instead of a complete "fusion" 131092 with 294 amino acids. Doc -12- 200914378 ID NO: 1 6). However, the truncated residue should have at least 2, preferably at least 3, 5 amino acids. For example, a residue having a truncation of from 2 to 293, preferably from 25 to 250, more preferably from 35 to 150 amino acids (e.g., 35 to 1 amino acid) can be used. One of the examples of this protein is yaad40-Xa-dewA-his (SEQ ID ΝΟ·.26 in PCT/EP 2006/064720) having a yaad residue truncated to 4 胺 amino groups. The splitting point between the hydrophobin and one or more fusion targets can be used to separate the fusion target and release the underivatized pure hydrophobin (eg, BrCN splitting)
甲硫胺酸、因子Xa分裂、腸肽酶分裂、凝血酶分裂、丁ev 分裂等)。 根據本發明作爲結晶輔助劑使用的疏水蛋白可經由已知 的肽合成法化學製備,例如經由Merrifield固相合成。 自然產生的疏水蛋白可從天然源中經由適宜方法單離。 可參考例如:w6sten等人,Eur. J Cell Bi〇 63, 122 129 (1994)或 WO 96/41882。 從嗜熱黃絲曲黴(Talar〇myces therm〇philus)中製造無融 合對象的疏水蛋白的基因卫程法說明於训2嶋鳩彻的。 人融σ蛋白&由基因工程方法製備較佳,纟中合併編碼融 5對象的核芽酸序列與編碼疏水蛋白部分的核普酸序列, 、八ΝΑ序列,使合併的核苷酸序列的基因表現, I物中產生所需蛋…該製造方法揭示於例如由侧 =ΓΓΓ:〇2°_253。該等融合對象極利於製 於無融合對象的疏水蛋白。 ,4大 131092.doc •13· 200914378 從侣主生物中經由基因工程方法製造的融合疏水蛋白可 依原則上0知的方式處理,且經h知色譜法純化。 冰一項較佳實施例使用w〇2_⑽22w頁揭 簡易處理及純化方法。因此,先 无從發酵液_分離發酵的细 Γ ϋ 胞,經破裂及從包涵體中分離細胞碎片。後者最好經離 心。最後,包涵體經原則上已知的方式破裂,例如,芦由 酸、鹼及/或清潔劑,釋放融合疏水蛋白。具有根據林 明使用的融合疏水蛋白的包涵體通常可在約…完全‘ 解’即使在使用0.1 μ NaOH情況下。 本發明具體實施财,得到的溶液可未經進—步純化即 可使用。但’融合疏水蛋白亦可從溶液中呈固體分離。較 佳經由噴霧乾燥分離,如動2_㈣⑸中12頁所述。瘦 簡^處理及純化方法得到的產物通常包含約8〇重量。A至卯 重量%蛋白質及細胞碎片殘餘物。融合疏水蛋白含量通常 占總蛋白質含量30重量%至8〇重量% ’隨融合構築體與發 酵條件而變。 包含融合疏水蛋自的分離產物呈固體儲存且溶解在特定 需要的介質中進行使用。 該融合疏水蛋白或在分裂及移除融合對象後呈”純,,疏水 蛋白實施本發I宜在分離及其溶解包涵體後進行分裂。 根據本發明’疏水蛋白在固體結晶中作爲輔助劑使用, 在該疏水蛋白存在下影響結晶。 本發明一項較佳實施例包含從液相中結晶固體。該液相 包含一種或多種溶劑、經溶解的固體及/或用於製造的原 131092.doc -14- 200914378 水蛋白及視需要選用的其他組分(例如其 物質)。溶劑或溶劑混合物的選擇在原則上不 … 需結晶的固體及疏水蛋白在其中具有足夠的可溶性。= 相關技藝之人士可根據需結晶的固體做出適宜的選擇。 =較佳包含水相。咸了解’術語"水相”為所使 包含占所有溶劑總含量的至少50重量%的水。水含 ί ::°重量%’更佳為至少9°重量%。可能的共溶劑包 3可與水混溶的溶劑,例如醇類(例如甲醇、乙醇 醇)。溶劑僅包含水特別佳。 或丙 習此相關技藝之人士可根據需結晶固體的特性及根據固 體所需的性質選擇水相阳。根據本發明,疏水蛋白(較佳 為融合疏水蛋白)在吨4下使用較佳,尤其為⑴ 範圍較佳在5至13之間,更佳在6至12之間,最佳為 之間。 Ο 習此相關技藝之人士可根據需結晶固體的特性及根據固 體所需的性質選擇疏水蛋白用量。通常該用量少於水相所 有成分總含量的i重量%較佳。疏水蛋白較佳用量為 重量%至1重量%,更佳為〇.〇〇1重量%至〇2重量 原則上所有從液相中結晶的方式均可能。—種可能性為 例如•結晶方法,並中作用UI科从从 八T使用固體的飽和溶液並經由蒸發溶 劑、冷卻或混合另-種不溶解該固體的溶劑,引發固體結 晶。另-種可能性為反應性沉殺法,其中僅由可溶性組份 相互反應,在水相中形成固體。 本發明-項特別佳實施例使用上述融合疏水蛋白。例 13W92.doc -15- 200914378 如’可使用 yaaci-Xa_dewA-his(SEQ ID ΝΟ··20),亦及尤其 八有、扭截斷的yaad殘基的蛋白質,例如yaad40-Xa-dewA-hlS。最好使用經由上述簡化的純化方法得到的產物。 疏水蛋白適用爲使無機及有機固體從液相中結晶的辅助 疏X蛋白尤其作爲結晶石膏(Cas〇4.2H2〇)的輔助劑。 所知曰曰體並非針狀晶體,反而得到更多更易從水相中分離 且具有明顯更小的長度/厚度比率的緻密晶體。 疏水蛋白進一步用於使碳酸妈結晶。Methionine, Factor Xa cleavage, intestinal peptidase cleavage, thrombin cleavage, Ding ev splitting, etc.). The hydrophobin used as a crystallizing aid according to the present invention can be chemically prepared by known peptide synthesis methods, for example, via Merrifield solid phase synthesis. Naturally occurring hydrophobins can be isolated from natural sources via suitable methods. Reference may be made, for example, to w6sten et al., Eur. J Cell Bi〇 63, 122 129 (1994) or WO 96/41882. The gene guard method for producing hydrophobins from unblended subjects from Talar〇myces therm〇philus is described in the training. The human sigma protein & is prepared by a genetic engineering method, and the nucleoside sequence encoding the fused 5 protein and the nucleotide sequence encoding the hydrophobin moiety, and the gossip sequence are combined to make the combined nucleotide sequence Gene expression, I produce the desired egg... This manufacturing method is disclosed, for example, by side = ΓΓΓ: 〇 2 ° 253. These fusion targets are highly advantageous for the production of hydrophobins from unfused objects. , 4 large 131092.doc •13· 200914378 The fusion hydrophobin produced by the genetic engineering method from the host organism can be processed in a manner known in principle, and purified by chromatography. A preferred embodiment of ice is a simple treatment and purification method using w〇2_(10)22w. Therefore, the fine cells of the fermented liquid are not separated from the fermentation broth, and the cell debris is separated from the inclusion body by rupture. The latter is best separated. Finally, the inclusion bodies are broken in a manner known per se, for example, the release of the fusion hydrophobin by acid, alkali and/or detergent. Inclusion bodies with fused hydrophobins used according to Lin Ming can generally be "completely" solved, even with 0.1 μl of NaOH. The present invention is specifically practiced, and the resulting solution can be used without further purification. However, the fusion hydrophobin can also be isolated as solids from solution. Preferably, it is separated by spray drying as described on page 12 of Motion 2_(4)(5). The product obtained by the thinning process and the purification method usually contains about 8 ounces by weight. A to 重量 Weight % protein and cell debris residue. The fusion hydrophobin content typically ranges from 30% to 8% by weight of the total protein content' depending on the fusion construct and the fermentation conditions. The isolated product comprising the fused hydrophobic egg is stored as a solid and dissolved in a specific desired medium for use. The fusion hydrophobin is "pure" after cleavage and removal of the fusion object, and the hydrophobin is subjected to cleavage after isolation and dissolution of the inclusion body. According to the invention, the hydrophobin is used as an adjuvant in solid crystallization. In the presence of the hydrophobin, crystallization is affected. A preferred embodiment of the invention comprises crystallizing a solid from a liquid phase comprising one or more solvents, dissolved solids and/or the original 131092.doc for use in the manufacture. -14- 200914378 Water protein and other components (such as its substances) as needed. The choice of solvent or solvent mixture is not in principle... Solids and hydrophobins to be crystallized are sufficiently soluble in them. A suitable choice can be made depending on the solid to be crystallized. = Preferably comprises the aqueous phase. The term 'aqueous' is used to include at least 50% by weight of water, based on the total content of all solvents. The water contains ί:°% by weight' more preferably at least 9% by weight. Possible cosolvent packages 3 are water miscible solvents such as alcohols (e.g., methanol, ethanol alcohol). The solvent contains only water particularly well. Or those skilled in the art can select the phase of the liquid according to the characteristics of the solid to be crystallized and according to the desired properties of the solid. According to the present invention, a hydrophobin (preferably a fusion hydrophobin) is preferably used at a ton of 4, particularly preferably a range of (1) preferably between 5 and 13, more preferably between 6 and 12, most preferably between.人士 Those skilled in the art can select the amount of hydrophobin according to the characteristics of the crystalline solid to be used and the properties required for the solid. Usually, the amount is less than i% by weight based on the total content of all components of the aqueous phase. The hydrophobin is preferably used in an amount of from 1% by weight to 1% by weight, more preferably from 重量1% by weight to 〇2 by weight. In principle, all means of crystallization from the liquid phase are possible. A possibility is, for example, a crystallization method, and the effect of the UI section is to initiate solid crystallization from a saturated solution of solids from eight T and by evaporating the solvent, cooling or mixing another solvent which does not dissolve the solid. Another possibility is the reactive killing method in which only the soluble components react with each other to form a solid in the aqueous phase. A particularly preferred embodiment of the invention is the use of the above-described fusion hydrophobin. Example 13W92.doc -15- 200914378 For example, yaaci-Xa_dewA-his (SEQ ID ΝΟ··20), and especially a protein with a singularly truncated yaad residue, such as yaad40-Xa-dewA-hlS, can be used. It is preferred to use the product obtained by the above simplified purification method. The hydrophobin is suitable as an auxiliary for the crystallization of inorganic and organic solids from the liquid phase, especially as an adjuvant for crystalline gypsum (Cas〇4.2H2〇). It is known that the corpus callosum is not a needle-like crystal, but instead obtains more dense crystals which are more easily separated from the aqueous phase and have a significantly smaller length/thickness ratio. Hydrophobin is further used to crystallize carbonic acid.
在本發明一項較佳實施例中,疏水蛋白可用在一種經由 從水相中結晶並從水相中移除形成的固體而製造固體之方 法。該製法特別適用於移除石膏的方法。 一以上描述了結晶步驟及較佳條件。固體(較佳為石膏)可 藉由習此相關技藝之人士所知的方法移除,例如經由過濾 或分離液體與固體的多種方法之組合。分離後,濕固體 經乾燥及進一步處理。 本發明方法可㈣包括煙氣脫硫方法。在㈣氣脫硫方 法中’第-階段包括使煙氣中存在的氣態吻在習此相關 技藝之人士所知的祕器中,與CaC()3水性懸浮液反應, 形成caS〇3,再經〇2氧化形成CaS〇4,呈Cas〇42帥结晶 析出。因此’經由該反應在水相中連續形成石f。欲控制 B曰孓日T,依上述濃度添加疏水蛋白至處理水中。 煙氣脫硫方法為習此相關技蓺 又;4人士所知。例如S02與In a preferred embodiment of the invention, the hydrophobin can be used in a process for making a solid by solidification formed by crystallization from an aqueous phase and removal from the aqueous phase. This method is particularly suitable for the method of removing gypsum. More than one describes the crystallization step and preferred conditions. The solid, preferably gypsum, can be removed by methods known to those skilled in the relevant art, for example, by a combination of various methods of filtering or separating liquids and solids. After separation, the wet solid is dried and further processed. The method of the invention may (iv) include a flue gas desulfurization process. In the (four) gas desulfurization process, the 'stage-stage includes the reaction of the gaseous kisses present in the flue gas with the CaC()3 aqueous suspension to form caS〇3, in a secret device known to those skilled in the art. Oxidation by 〇2 forms CaS〇4, which is precipitated as Cas〇42. Therefore, the stone f is continuously formed in the aqueous phase via the reaction. To control B. T, add hydrophobin to the treated water at the above concentrations. The flue gas desulfurization method is a related skill; 4 people know. Such as S02 and
CaCCh的反應可依逆流方式進 丁无在紋液分離器中以濃 縮的石膏懸浮液形式分離所形成的春曰 紙07七用日日體,然後經由過 131092.doc -16· 200914378 濾、沖洗及乾燥來回收固體。進一步細節參考紐約2006, Weinheim, Wiley-VCH, Electronic 發行,2006 第 7 版,The CaCCh reaction can be carried out in a countercurrent manner without the separation of the concentrated gypsum suspension in the lysate separator, which is formed by the concentrated gypsum suspension, and then filtered and rinsed through 131092.doc -16· 200914378. And dry to recover solids. Further details refer to New York 2006, Weinheim, Wiley-VCH, Electronic Release, 2006 7th Edition,
Ullmann's Encyclopedia of Industrial Chemistry 中”Calcium Sulfate-3,2 Flue Gas Desulphurization (FDG) Gypsum",及 其中引用的參考文獻。形成的石膏隨後經燒熔(形成脫水 物)且依已知方式用於例如建築材料工業中。 以下實例闡述本發明: 提供疏水蛋白 該等發明利用具有完整融合對象yaad(yaad_Xa_dewA_ his,以下稱為疏水蛋白a)的融合疏水蛋白及具有截斷至 40個胺基酸的融合對象,yaa(j4〇-Xa-dewA-his(疏水蛋白 B)的融合疏水蛋白。此等按照w〇 2006/082253中描述的 步驟製備。 產物經由WO 2〇06/82253實例9的簡易純化方法處理,且 按照同一參考文獻實例1 〇經喷霧乾燥。在每種情況下,得 到的乾產物之總蛋白質含量為約70%至95重量❶/。,疏水蛋 白含量占總蛋白質含量的約40%至90重量%。該等產物即 用於實驗。 性能實驗:由水滴在玻璃上的接觸角變化確定融合疏水蛋 白的特徵 基質: 玻璃(窗戶玻璃,Siiddeutsche Glas,Mannheim) 於該等實驗,取包含融合疏水蛋白的喷霧乾燥產物溶解 在含50 mm pH 4的醋酸鈉與0>1重量%聚氧乙烯(2〇)山梨糖 131092.doc 200914378 醇酐單月桂酸酯(Tween®20)之水中。產物濃度:100 pg/mL之水溶液。 步驟: -玻璃載片培養隔夜(8〇艺),然後以蒸餾水洗滌塗層, -然後培養10分鐘/8〇。〇/1 %十二烷基磺酸鈉(SDS)之蒸镏 水溶液, -以蒸餾水沖洗"Calcium Sulfate-3, 2 Flue Gas Desulphurization (FDG) Gypsum", and references cited therein in Ullmann's Encyclopedia of Industrial Chemistry. The formed gypsum is subsequently fired (forming an anhydrate) and used in a known manner for example in construction In the materials industry, the following examples illustrate the invention: Providing hydrophobins. The invention utilizes a fusion hydrophobin with a complete fusion target yaad (yaad_Xa_dewA_hi, hereinafter referred to as hydrophobin a) and a fusion object with a cutoff of 40 amino acids. a fusion hydrophobin of yaa (j4〇-Xa-dewA-his (hydrophobin B). These were prepared according to the procedure described in WO 2006/082253. The product was treated via the simple purification method of Example 2 of WO 2〇06/82253, And spray dried according to the same reference example 1. In each case, the total protein content of the obtained dry product is about 70% to 95% by weight, and the hydrophobin content is about 40% of the total protein content. 90% by weight. These products were used for experiments. Performance test: Determination of the characteristic matrix of the fusion hydrophobin by the change of the contact angle of water droplets on the glass Glass (Window Glass, Siiddeutsche Glas, Mannheim) In these experiments, a spray-dried product containing fused hydrophobin was dissolved in sodium acetate containing 50 mm pH 4 and 0 gt; 1 wt% polyoxyethylene (2 〇) sorbose 131092.doc 200914378 Alcoholic anhydride monolaurate (Tween®20) in water. Product concentration: 100 pg/mL aqueous solution. Procedure: - Glass slide culture overnight (8 〇 art), then wash the coating with distilled water, - Then incubated for 10 minutes / 8 〇. 〇 / 1% sodium dodecyl sulfonate (SDS) in distilled water, - rinsed with distilled water
樣品於空氣中乾燥,且在室溫下測定5 μ1水滴的接觸角 (以度為單位)。 經由 Dataphysics Contact Angle System OCA 15+,軟體 SCA 20.2.0(2002年U月)測量接觸角。根據使用説明書進 行測量。 未處理玻璃接觸角為15。至30。±5。。融合疏水蛋白yaad. Xa-dewA-his6塗層使接觸角增加3〇。以上;融合疏水蛋白 yaad40-Xa-dewA-his塗層同樣使接觸角增加3〇。以上。 石膏結晶實驗 一般操作步驟 於完全去離子水中製備CaS〇4.2H2〇飽和溶液(濃度約2 g")。每份該溶液分別與疏水蛋白A及疏水蛋白b混合,使 石膏溶液的噴霧乾燥產物濃度達約〇.1 8/卜分別經口由二 與NaOH調節溶液ρί^藉由折疊式過濾器(約1〇過濾水 性溶液/懸浮液。然後,取約25 ml每種溶液轉移至培養^ 中’且在約24小時内在室溫下蒸發水份。以添加 的溶液作為對照組。 蛋白 131092.doc -18- 200914378 圖]$ 6八 阳體形式採用〇lympus的BH-2顯微鏡比較 为別顯示所得晶體的顯微圖像(40倍放大率— 情況下粒度約0.01_0.lmm) ’母 討論The sample was dried in air and the contact angle (in degrees) of 5 μl water droplets was measured at room temperature. The contact angle was measured via Dataphysics Contact Angle System OCA 15+, software SCA 20.2.0 (U-2002). Make measurements according to the instruction manual. The untreated glass has a contact angle of 15. To 30. ±5. . The fusion hydrophobin yaad. Xa-dewA-his6 coating increased the contact angle by 3 〇. Above; fusion of hydrophobin yaad40-Xa-dewA-his coating also increased the contact angle by 3〇. the above. Gypsum Crystallization Experiment General Procedures Prepare a saturated solution of CaS〇4.2H2 in fully deionized water (concentration approx. 2 g"). Each solution is mixed with hydrophobin A and hydrophobin b, respectively, so that the concentration of the spray dried product of the gypsum solution is about 1.1 8 / 卜 respectively by the two and NaOH to adjust the solution ρί^ by the folding filter (about 1 〇 Filter the aqueous solution/suspension. Then, transfer about 25 ml of each solution to the culture and evaporate the water at room temperature for about 24 hours. Add the solution as a control. Protein 131092.doc - 18- 200914378 Figure] $6 eight-mass form using a Hlympus BH-2 microscope to compare the microscopic images of the crystals obtained (40 times magnification - in the case of a particle size of about 0.01_0.lmm)
圖1至6顯示石膏晶形可由疏水蛋白影響。在無輔助劑及 在仲8下沉澱的石膏包含長度/厚度比率約1〇的針狀體⑽ 0。加入疏水蛋白A(圖2)或疏水蛋白B(圖3),在pH 8下沉 淀的石膏不具有針狀體;反之,得到具有長度/厚度比率 約2至3的f密棱柱。相較於未加疏水蛋白的實驗,針狀體 長度明顯截斷。此等緊密顆粒具有更好的過濾性質。 針狀體長度在所有pH值下均被疏水蛋白截斷(圊4至6)。 該效應在鹼性範圍内最顯著(圖1至3及6),其中幾乎僅得到 棱柱且無任何針狀體。 【圖式簡單說明】Figures 1 to 6 show that the gypsum crystal form can be affected by hydrophobin. The gypsum precipitated in the absence of an adjuvant and under the secondary 8 contains a needle-like body (10) 0 having a length/thickness ratio of about 1 。. Upon addition of hydrophobin A (Fig. 2) or hydrophobin B (Fig. 3), the gypsum precipitated at pH 8 did not have needles; conversely, a dense prism having a length/thickness ratio of about 2 to 3 was obtained. The length of the needle was significantly truncated compared to the experiment without hydrophobin. These compact particles have better filtration properties. The length of the needle is truncated by hydrophobin at all pH values (圊4 to 6). This effect is most pronounced in the alkaline range (Figures 1 to 3 and 6), where almost only prisms are obtained and no needles are present. [Simple description of the map]
圖1 pH 8,未添加疏水蛋白 圖2 pH 8,添加疏水蛋白A 圖3 pH 8,添加疏水蛋白B 圖4 pH 4,添加疏水蛋白B 圖5 pH 6,添加疏水蛋白B 圖6 pH 1 〇,添加疏水蛋白B 131092.doc -19·Figure 1 pH 8, no hydrophobin added Figure 2 pH 8, add hydrophobin A Figure 3 pH 8, add hydrophobin B Figure 4 pH 4, add hydrophobin B Figure 5 pH 6, add hydrophobin B Figure 6 pH 1 〇 , adding hydrophobin B 131092.doc -19·
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07108856 | 2007-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200914378A true TW200914378A (en) | 2009-04-01 |
Family
ID=39684302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW097118950A TW200914378A (en) | 2007-05-24 | 2008-05-22 | Use of hydrophobins as auxil auxiliaries in the crystallization of solids |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100166627A1 (en) |
| EP (1) | EP2155611A1 (en) |
| JP (1) | JP2010527886A (en) |
| KR (1) | KR20100022482A (en) |
| CN (1) | CN101679063A (en) |
| CA (1) | CA2687490A1 (en) |
| CL (1) | CL2008001513A1 (en) |
| MX (1) | MX2009012309A (en) |
| RU (1) | RU2009147812A (en) |
| TW (1) | TW200914378A (en) |
| WO (1) | WO2008142111A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4772110B2 (en) * | 2005-03-31 | 2011-09-14 | ビーエーエスエフ ソシエタス・ヨーロピア | Use of polypeptides as adhesion promoters |
| DE102005033002A1 (en) * | 2005-07-14 | 2007-01-18 | Basf Ag | Aqueous monomer emulsions containing hydrophobin |
| CN102089051A (en) * | 2008-07-11 | 2011-06-08 | 巴斯夫欧洲公司 | Amphiphilic proteins as morphology modifiers |
| JP5623416B2 (en) * | 2008-11-03 | 2014-11-12 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | Photoinitiator mixture |
| JP2012509921A (en) | 2008-11-27 | 2012-04-26 | ビーエーエスエフ ソシエタス・ヨーロピア | Surface active proteins as excipients in solid pharmaceutical formulations |
| WO2010097344A1 (en) | 2009-02-26 | 2010-09-02 | Basf Se | Compositions, use and method for the use of surface active proteins in topical drug delivery across keratin |
| WO2011015530A2 (en) | 2009-08-03 | 2011-02-10 | Basf Se | Process for deposition of thin layers of metal oxides |
| CN103476785A (en) * | 2011-04-15 | 2013-12-25 | 丹尼斯科美国公司 | Methods of purifying hydrophobin |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB562561A (en) * | 1942-12-17 | 1944-07-06 | Cuthbert Leslie Haddon | Improvements in the manufacture of plaster of paris |
| US4183908A (en) * | 1977-06-24 | 1980-01-15 | Southern California Edison Company | Crystalline calcium sulfate dihydrate and process for making same |
| JPS5532789A (en) * | 1979-08-14 | 1980-03-07 | Hiyougoken | Production of hexagonal prismatic crystal alpha-type hemihydrate gypsum |
| DE3522494A1 (en) * | 1985-06-24 | 1987-01-02 | Heinrich Quante | Process for controlling crystallization from solutions and apparatus for carrying out the process |
| US5246677A (en) * | 1991-05-07 | 1993-09-21 | Electric Power Research Institute | Addition of organophosphonates for size control of wet calcium-based FGD byproduct solids under forced oxidation conditions |
| US7241734B2 (en) * | 2004-08-18 | 2007-07-10 | E. I. Du Pont De Nemours And Company | Thermophilic hydrophobin proteins and applications for surface modification |
| JP5250264B2 (en) * | 2005-02-07 | 2013-07-31 | ビーエーエスエフ ソシエタス・ヨーロピア | Novel hydrophobin fusion protein, its production and use |
| TW200639179A (en) * | 2005-02-07 | 2006-11-16 | Basf Ag | Method for coating surfaces with hydrophobins |
| KR101250067B1 (en) * | 2005-03-30 | 2013-04-03 | 바스프 에스이 | Use of hydrophobin for hard surface soil-repellent treatment |
| CA2602706C (en) * | 2005-04-01 | 2013-01-08 | Basf Aktiengesellschaft | Drilling fluid containing hydrophobin |
| MX2007011125A (en) * | 2005-04-01 | 2007-10-23 | Basf Ag | Use of proteins as demulsifying agents. |
| DE102005025969A1 (en) * | 2005-06-03 | 2006-12-28 | Basf Ag | Reduction of evaporation rate of water in an open water reservoir, comprises mixing of hydrophobin fusion protein with water and/or biodegradable barrier liquid having hydrocarbon mixture |
| DE102005027139A1 (en) * | 2005-06-10 | 2006-12-28 | Basf Ag | New cysteine-depleted hydrophobin fusion proteins, their production and use |
| EP1913123B1 (en) * | 2005-08-01 | 2010-10-20 | Basf Se | Use of surface-active non-enzymatic proteins for washing textiles |
-
2008
- 2008-05-21 CA CA002687490A patent/CA2687490A1/en not_active Abandoned
- 2008-05-21 US US12/601,281 patent/US20100166627A1/en not_active Abandoned
- 2008-05-21 RU RU2009147812/05A patent/RU2009147812A/en not_active Application Discontinuation
- 2008-05-21 EP EP08759865A patent/EP2155611A1/en not_active Withdrawn
- 2008-05-21 KR KR1020097026772A patent/KR20100022482A/en not_active Withdrawn
- 2008-05-21 MX MX2009012309A patent/MX2009012309A/en unknown
- 2008-05-21 JP JP2010508843A patent/JP2010527886A/en not_active Withdrawn
- 2008-05-21 CN CN200880017298A patent/CN101679063A/en active Pending
- 2008-05-21 WO PCT/EP2008/056263 patent/WO2008142111A1/en not_active Ceased
- 2008-05-22 TW TW097118950A patent/TW200914378A/en unknown
- 2008-05-23 CL CL2008001513A patent/CL2008001513A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2009012309A (en) | 2009-12-01 |
| KR20100022482A (en) | 2010-03-02 |
| WO2008142111A1 (en) | 2008-11-27 |
| US20100166627A1 (en) | 2010-07-01 |
| RU2009147812A (en) | 2011-06-27 |
| CA2687490A1 (en) | 2008-11-27 |
| JP2010527886A (en) | 2010-08-19 |
| CN101679063A (en) | 2010-03-24 |
| EP2155611A1 (en) | 2010-02-24 |
| CL2008001513A1 (en) | 2009-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200914378A (en) | Use of hydrophobins as auxil auxiliaries in the crystallization of solids | |
| CN101891807B (en) | Canola protein isolate compositions | |
| CN106946795A (en) | Substituted dicarbamylamine and diaminourea formonitrile HCN pyrimidine, its composition, and the method treated with it | |
| Bae et al. | Asymmetric maltose neopentyl glycol amphiphiles for a membrane protein study: effect of detergent asymmetricity on protein stability | |
| TW201639867A (en) | Peptide synthesis method | |
| RS55218B1 (en) | FIBRONECTIN TYPE III COMPOSITIONS OF SCALE-BASED DOMAINS, METHODS AND USES | |
| JP2008504016A (en) | Mussel adhesion protein | |
| JP6959251B2 (en) | Site-specific bioconjugation methods and compositions useful for nanopore systems | |
| CN103254316A (en) | Antimicrobial peptide with drug-resistance bacteria resistance activity and synthesis and application thereof | |
| CN113754738B (en) | A polypeptide monomer molecule and its self-assembled nanomaterials and applications | |
| Putta et al. | Lipid− protein interactions for ECA1 an N-ANTH domain protein involved in stress signaling in plants | |
| US11154636B2 (en) | Antimicrobial biopolymer compositions, methods of synthesis, and applications of use | |
| JP7018075B2 (en) | Combination of methotrexate and peptide | |
| CN113874090B (en) | Method for the aqueous extraction of biosurfactants from corn steep water | |
| CN110294793B (en) | SUMO fluorescent probe and preparation method thereof | |
| WO2008136820A1 (en) | Stabilization of mammalian membrane proteins by short surfactant peptides | |
| JP5745229B2 (en) | Sericin with enhanced hydrophobicity and method for producing the same | |
| Messina et al. | From nanoaggregates to mesoscale ribbons: the multistep self-organization of amphiphilic peptides | |
| JP2022513711A (en) | Amphipole | |
| CN109666061B (en) | Surfactant and preparation method and application thereof, emulsion | |
| JP2019116449A (en) | Oral composition | |
| CN106957370A (en) | It is a kind of to trigger the polypeptide of toxicity in tumour cell | |
| CN112898172A (en) | Synthesis method of amphiphilic functional group compound capable of being enzymolyzed by carboxypeptidase | |
| WO2006115230A1 (en) | Compound having amino acid residue or peptide residue and process for producing the same | |
| CN111548393B (en) | Linear peptide molecule and application thereof |